HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus.

AbstractPURPOSE:
Temsirolimus is an effective treatment for renal cell carcinoma. It is associated with increases in serum cholesterol, triglyceride, and glucose. We investigated whether changes of these biomarkers could predict its efficacy.
EXPERIMENTAL DESIGN:
We examined serial measurements of cholesterol, triglycerides, and glucose from patients randomized to IFN or temsirolimus in the Global Advanced Renal Cell Carcinoma Trial. Using time-dependent proportional hazards models, we quantified the association between changes in these biomarkers from baseline with overall survival (OS) and progression-free survival (PFS). We also assess the extent to which changes of these biomarkers predict the effects of temsirolimus on survival.
RESULTS:
Temsirolimus was associated with larger mean increases in cholesterol (1.02 mmol/L; P < 0.0001), triglycerides (0.32 mmol/L; P = 0.0008), and glucose (1.28 mmol/L; P < 0.0001) compared with IFN and improved survival rate (OS: HR = 0.76, P = 0.02; PFS: HR = 0.70, P = 0.001). Cholesterol increase during study was associated with longer survival (OS: HR = 0.77 per mmol/L, P < 0.0001; PFS: HR = 0.81 per mmol/L; P < 0.0001). Temsirolimus effect on cholesterol predicted its effect on survival with no additional survival advantage observed after adjusting for cholesterol change during study (OS: HR = 1.14, P = 0.37; PFS: HR = 0.88, P = 0.35). Temsirolimus effect on triglycerides or glucose did not predict its effect on survival, with survival advantage in favor of temsirolimus still observed after adjusting for these factors (P = 0.003 and P = 0.002).
CONCLUSION:
Cholesterol increase is a potential predictor for temsirolimus efficacy. Longer survival in patients treated with temsirolimus was observed in those with larger increases in cholesterol. Prospectively designed biomarker studies of temsirolimus or other mTOR inhibitors are recommended.
AuthorsChee Khoon Lee, Ian C Marschner, R John Simes, Merryn Voysey, Brian Egleston, Gary Hudes, Paul de Souza
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 18 Issue 11 Pg. 3188-96 (Jun 1 2012) ISSN: 1078-0432 [Print] United States
PMID22472176 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Blood Glucose
  • Triglycerides
  • temsirolimus
  • Cholesterol
  • Sirolimus
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents (therapeutic use)
  • Biomarkers, Tumor (blood)
  • Blood Glucose
  • Carcinoma, Renal Cell (blood, drug therapy, mortality)
  • Cholesterol (blood)
  • Disease-Free Survival
  • Female
  • Humans
  • Kidney Neoplasms (blood, drug therapy, mortality)
  • Male
  • Middle Aged
  • Prognosis
  • Sirolimus (analogs & derivatives, therapeutic use)
  • Triglycerides (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: